

A1
drugs, agents and the like. However, further opportunities for particularly selective targeting of diagnostic and/or therapeutic agents to tissues or cells of interest, by means of a rationally designed prodrug conjugate remain.

Please replace the paragraph beginning at page 5, line 2 with the following:

A2
When Z includes at least one amino acid residue, the amino acid is, e.g., alanine, valine, leucine, isoleucine, glycine, serine, threonine, methionine, cysteine, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, lysine, arginine, histidine, proline, and/or a combination thereof, to name but a few. When Z includes a peptide, the peptide ranges in size, for instance, from about 2 to about 10 amino acid residues. In one preferred embodiment, the peptide is Gly-Phe-Leu-Gly (SEQ ID NO: 1) or Gly-Phe-Leu.

Please replace the paragraph beginning at page 20, line 8 with the following:

A3
Suitable amino acid residues can be selected from naturally-occurring or synthetic, i.e. non-naturally-occurring, amino acids including alanine, valine, leucine, isoleucine, glycine, serine, threonine, methionine, cysteine, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, lysine, arginine, histidine or proline. Some preferred peptide residues include Gly-Phe-Leu-Gly (SEQ ID NO: 1) and Gly-Phe-Leu. It is noted that the terminal amino group of the amino acid or peptide residue will be proximal to R₁₁ (i.e. polymer). Peptides can be readily synthesized or obtained from commercial sources for inclusion herein.